{"id":39346,"date":"2025-08-14T14:42:54","date_gmt":"2025-08-14T06:42:54","guid":{"rendered":"https:\/\/flcube.com\/?p=39346"},"modified":"2025-08-14T14:42:55","modified_gmt":"2025-08-14T06:42:55","slug":"hualan-biological-gains-nmpa-approval-for-hib-vaccine-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39346","title":{"rendered":"Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials"},"content":{"rendered":"\n<p>Hualan Biological Engineering Inc., (<a href=\"https:\/\/www.google.com\/finance\/quote\/002007:SHE\">SHE: 002007<\/a>) announced that its freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine has received approval from China&#8217;s National Medical Products Administration (NMPA) to initiate clinical trials. The vaccine is designed to prevent invasive infections caused by Hib, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, and other conditions.<\/p>\n\n\n\n<p><strong>Vaccine Overview<\/strong><br>The Hib vaccine developed by Hualan is formulated by conjugating purified Hib capsular polysaccharide with tetanus toxoid protein. This formulation is presented in a freeze-dried form. The vaccine aims to induce an immune response against Hib, providing protection to vaccinated individuals.<\/p>\n\n\n\n<p><strong>Clinical Trial Approval<\/strong><br>The approval from the NMPA marks a significant milestone in the development of Hualan&#8217;s Hib vaccine. The company is now poised to advance into clinical trials, which will evaluate the safety and efficacy of the vaccine in preventing Hib-related infections.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u534e\u5170\u751f\u7269\uff1a\u5173\u4e8e\u516c\u53f8\u63a7\u80a1\u5b50\u516c\u53f8\u53d6\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u534e\u5170\u751f\u7269\uff1a\u5173\u4e8e\u516c\u53f8\u63a7\u80a1\u5b50\u516c\u53f8\u53d6\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-2b9e44af-0288-4180-8c2e-834ed4a27bb7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u534e\u5170\u751f\u7269\uff1a\u5173\u4e8e\u516c\u53f8\u63a7\u80a1\u5b50\u516c\u53f8\u53d6\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u534e\u5170\u751f\u7269\uff1a\u5173\u4e8e\u516c\u53f8\u63a7\u80a1\u5b50\u516c\u53f8\u53d6\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u534e\u5170\u751f\u7269\uff1a\u5173\u4e8e\u516c\u53f8\u63a7\u80a1\u5b50\u516c\u53f8\u53d6\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2b9e44af-0288-4180-8c2e-834ed4a27bb7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hualan Biological Engineering Inc., (SHE: 002007) announced that its freeze-dried Haemophilus influenzae type b (Hib)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":39352,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,4283,1564,12],"class_list":["post-39346","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hualan-biological-engineering","tag-she-002007","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hualan Biological Engineering Inc., (SHE: 002007) announced that its freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate clinical trials. The vaccine is designed to prevent invasive infections caused by Hib, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, and other conditions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39346\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"Hualan Biological Engineering Inc., (SHE: 002007) announced that its freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate clinical trials. The vaccine is designed to prevent invasive infections caused by Hib, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, and other conditions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39346\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-14T06:42:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-14T06:42:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1408.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39346#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39346\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials\",\"datePublished\":\"2025-08-14T06:42:54+00:00\",\"dateModified\":\"2025-08-14T06:42:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39346\"},\"wordCount\":154,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39346#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1408.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Hualan Biological Engineering\",\"SHE: 002007\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39346#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39346\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39346\",\"name\":\"Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39346#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39346#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1408.webp\",\"datePublished\":\"2025-08-14T06:42:54+00:00\",\"dateModified\":\"2025-08-14T06:42:55+00:00\",\"description\":\"Hualan Biological Engineering Inc., (SHE: 002007) announced that its freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials. The vaccine is designed to prevent invasive infections caused by Hib, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, and other conditions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39346#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39346\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39346#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1408.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1408.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39346#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Hualan Biological Engineering Inc., (SHE: 002007) announced that its freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials. The vaccine is designed to prevent invasive infections caused by Hib, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, and other conditions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39346","og_locale":"en_US","og_type":"article","og_title":"Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials","og_description":"Hualan Biological Engineering Inc., (SHE: 002007) announced that its freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials. The vaccine is designed to prevent invasive infections caused by Hib, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, and other conditions.","og_url":"https:\/\/flcube.com\/?p=39346","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-14T06:42:54+00:00","article_modified_time":"2025-08-14T06:42:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1408.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39346#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39346"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials","datePublished":"2025-08-14T06:42:54+00:00","dateModified":"2025-08-14T06:42:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39346"},"wordCount":154,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39346#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1408.webp","keywords":["Clinical trial approval \/ initiation","Hualan Biological Engineering","SHE: 002007","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39346#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39346","url":"https:\/\/flcube.com\/?p=39346","name":"Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39346#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39346#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1408.webp","datePublished":"2025-08-14T06:42:54+00:00","dateModified":"2025-08-14T06:42:55+00:00","description":"Hualan Biological Engineering Inc., (SHE: 002007) announced that its freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials. The vaccine is designed to prevent invasive infections caused by Hib, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, and other conditions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39346#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39346"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39346#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1408.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1408.webp","width":1080,"height":608,"caption":"Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39346#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1408.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39346"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39346\/revisions"}],"predecessor-version":[{"id":39353,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39346\/revisions\/39353"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39352"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}